ICON PLC

ICON PLC is a global provider of outsourced development and commercialization services to pharmaceutical, biotechnology, medical device, and government and public health organizations. The company offers a full range of clinical, consulting, and commercial services, spanning from clinical development strategy, planning, and trial design, to full study execution, and post-market commercialization. ICON provides its services through various clinical outsourcing operating models, including strategic partnerships, preferred provider, full-service delivery, functional service provision, and stand-alone services. ICON specializes in the strategic development, management, and analysis of programs supporting all stages of the clinical development process, from compound selection to Phase I-IV clinical studies. The company earns revenue by providing services such as clinical trial management, consulting, contract staffing, data solutions, and laboratory services, which are integral to the clinical development process. ICON is one of a select group of Contract Research Organizations (CROs) capable of conducting clinical trials in major therapeutic areas globally, with operational flexibility for stand-alone or integrated full-service solutions. The company invests in technology and data analytics capabilities, enhancing its portfolio of data solutions and decentralized clinical trial technology. At December 31, 2025, ICON employed approximately 40,100 employees across 97 locations in 55 countries. For the year ended December 31, 2025, 30.6% of revenue was derived from the United States, 57.9% from Europe, and 11.5% from the Rest of World.